Vanta Bioscience

Vanta Bioscience EPS

The Earnings per Share (EPS) of Vanta Bioscience (540729.BO) as of Oct 27, 2026 is -7.56 INR. In the previous year, Earnings per Share (EPS) was -3.67 INR — a change of 106.18% (lower).

EPS

-7.56INR

YoY

106.18%

Last updated:

Earnings per Share (EPS) of Vanta Bioscience is 2025 -7.56 INR. Earnings per Share (EPS) of Vanta Bioscience was 2024 -3.67 INR. It decreases by 106.18% lower compared to the previous year.

The Vanta Bioscience EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
0.05 INR
Jan 1, 2019
1.10 INR
Jan 1, 2020
1.59 INR
Jan 1, 2021
0.71 INR
Jan 1, 2022
0.14 INR
Jan 1, 2023
-10.27 INR
Jan 1, 2024
-3.67 INR
Jan 1, 2025
-7.56 INR
The Vanta Bioscience EPS history
YEAREPSYoY
-7.56INR+106.18%
-3.67INR-64.26%
-10.27INR-7,446.88%
0.14INR-80.38%
0.71INR-55.25%
1.59INR+44.23%
1.10INR+2,106.84%
0.05INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vanta Bioscience Stock analysis

What does Vanta Bioscience do? Vanta Bioscience Ltd. generates revenue by offering comprehensive preclinical contract research services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. The company provides preclinical safety assessment services, risk assessment for active pharmaceutical ingredients (API), excipients, extractable and leachable substances, and pharmaceutical impurities. It also delivers health-based exposure limit determinations including permitted daily exposure (PDE), allowable daily exposure (ADE), and occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's clients across diverse sectors rely on its analytical testing, environmental studies, and research services for regulatory compliance and product safety validation. Vanta Bioscience Ltd. operates as a full-service preclinical contract research organization with a focus on delivering specialized safety assessments and exposure limit evaluations to support client product development and market entry. Its service portfolio includes clinical research, pre-clinical research, biopharma services, analytical testing, and environmental studies, catering to industries requiring rigorous safety evaluations before product launch. The company's expertise in risk assessment for pharmaceutical ingredients and related substances enables it to serve a broad range of clients in the biopharma and chemical sectors. Vanta Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vanta Bioscience stock

Earnings per Share (EPS) of Vanta Bioscience is -7.56 INR in 2025.

Earnings per Share (EPS) of Vanta Bioscience changed from -3.67 INR to -7.56 INR, representing a 106.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Vanta Bioscience since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vanta Bioscience

All Key Metrics — Vanta Bioscience